Tirzepatide Beats Semaglutide for Fat Loss, but Not Because It Kills Appetite More

Secondary analysis of a randomized, double-blind, parallel-arm Phase 2 study. Type 2 diabetes patients received tirzepatide 15 mg (n=45), semaglutide 1 mg (n=44), or placebo (n=28) for 28 weeks. Body composition was assessed (fat mass vs lean mass). Appetite was measured by visual analog scales. Energy intake was measured during ad libitum lunch meals.

Tirzepatide consistently produces more weight loss than semaglutide in clinical trials, but why has been unclear. This study reveals that appetite suppression alone doesn't explain the difference — both drugs reduce hunger similarly. This means the dual GIP/GLP-1 mechanism of tirzepatide must provide additional metabolic benefits, possibly through increased fat burning or energy expenditure, that go beyond simply eating less. Understanding these mechanisms could inform the development of even more effective peptide-based obesity treatments.

This finding has major implications for the peptide drug obesity pipeline. If tirzepatide's advantage over semaglutide isn't about appetite, then the GIP receptor — which tirzepatide activates but semaglutide doesn't — may drive metabolic benefits like fat oxidation or energy expenditure. This supports development of drugs that target metabolic pathways beyond appetite, potentially leading to even more effective weight-loss medications.

This is a secondary analysis of a trial not primarily designed for these endpoints. The sample size is small (117 total). Energy intake was only measured during a single ad libitum lunch, not over 24 hours — other meals may differ. Semaglutide was dosed at 1 mg (not 2.4 mg, the obesity dose), so the comparison may not reflect maximal semaglutide efficacy. The mechanisms explaining tirzepatide's greater weight loss were not identified, only that appetite reduction isn't sufficient.